Education
About Us
Working with TipRanks
Follow Us
Xoma Corp (XOMA)
NASDAQ:XOMA
XOMA Stock Chart & Stats
$26.97
$0.08(0.31%)
At close: 4:00 PM EST
$26.97
$0.08(0.31%)
Day’s Range― - ―
52-Week Range$18.35 - $39.92
Previous CloseN/A
Volume8.24K
Average Volume (3M)53.64K
Market Cap
$327.78M
Enterprise Value$375.41M
Total Cash (Recent Filing)$92.00M
Total Debt (Recent Filing)$131.91M
Price to Earnings (P/E)36.2
Beta1.33
Next Earnings
Mar 05, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.70
Shares Outstanding12,383,103
10 Day Avg. Volume49,949
30 Day Avg. Volume53,642
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)3.75
Price to Sales (P/S)10.79
P/FCF Ratio-22.33
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue7.97
Enterprise Value/Gross Profit8.50
Enterprise Value/Ebitda36.02
Forecast
1Y Price Target
$71.00Price Target Upside163.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Partnerships And RoyaltiesExpanded royalty agreement with Takeda covering nine additional assets adds small royalty percentages and potential milestone payments, increasing the company's non-dilutive revenue optionality.
Pipeline And Late-stage ProgramsA broad partnered pipeline that includes about ten late-stage programs and multiple Phase 3 assets creates opportunities for near-term milestone receipts and reduces single-program concentration risk.
Technology Monetization And Strategic AcquisitionsAcquisition of Generation Bio brings ownership of a ctLNP delivery platform tied to an existing collaboration with Moderna, creating prospects for future licensing revenue or asset monetization.
Bears Say
Clinical Trial SetbacksFailure of Rezolute's Phase 3 ersodetug trial to meet primary and secondary endpoints removes an expected development milestone and injects uncertainty into near-term royalty prospects.
Partner Financial Distress And Acquisition RiskGeneration Bio's cash burn leading to an acquisition highlights how partner liquidity problems can force distressed transactions that may reduce anticipated returns or delay royalty streams.
Revenue Visibility And Market ReactionRemoval of a near-term revenue driver from the company's P&L can lower revenue visibility and catalyze share weakness as analysts revise near-term forecasts.
Xoma News
XOMA FAQ
What was Xoma Corp’s price range in the past 12 months?
Xoma Corp lowest stock price was $18.35 and its highest was $39.92 in the past 12 months.
What is Xoma Corp’s market cap?
Xoma Corp’s market cap is $327.78M.
When is Xoma Corp’s upcoming earnings report date?
Xoma Corp’s upcoming earnings report date is Mar 05, 2026 which is in 29 days.
How were Xoma Corp’s earnings last quarter?
Xoma Corp released its earnings results on Nov 12, 2025. The company reported $0.7 earnings per share for the quarter, beating the consensus estimate of -$0.04 by $0.74.
Is Xoma Corp overvalued?
According to Wall Street analysts Xoma Corp’s price is currently Undervalued.
Does Xoma Corp pay dividends?
Xoma Corp does not currently pay dividends.
What is Xoma Corp’s EPS estimate?
Xoma Corp’s EPS estimate is -0.07.
How many shares outstanding does Xoma Corp have?
Xoma Corp has 12,383,103 shares outstanding.
What happened to Xoma Corp’s price movement after its last earnings report?
Xoma Corp reported an EPS of $0.7 in its last earnings report, beating expectations of -$0.04. Following the earnings report the stock price went down -2.522%.
Which hedge fund is a major shareholder of Xoma Corp?
Currently, no hedge funds are holding shares in XOMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xoma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$71.00 (163.26% Upside)
$71.00 (163.26% Upside)
Hedge Fund Trend
Increased
By 29.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 6.9%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.28%
12-Months-Change
Fundamentals
Return on Equity
16.22%
Trailing 12-Months
Asset Growth
-8.15%
Trailing 12-Months
Company Description
Xoma Corp
XOMA Royalty Corp. operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
XOMA Stock 12 Month Forecast
Average Price Target
$71.00
▲(163.26% Upside)
Technical Analysis
Ocugen
―
Corvus Pharmaceuticals
―
RAPT Therapeutics
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
13.18% Insiders
17.56% Mutual Funds
28.49% Other Institutional Investors
32.76% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---